Oncotalks hematology videos and news

ESMO 2019 Filippo Pietrantonio, MD, PhD; Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases​

Filippo Pietrantonio, MD, PhD from the University of Milan, Milan, Italy is commenting on the abstract 1878PD - Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

Related items

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania
00:03:29
ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Hungary , Lithuania , Albania
00:03:01
ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

prof. Sherko Kümmel, MD from the Kliniken Essen-Mitte, Essen, Germany is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Hungary , Lithuania , Albania , Slovenia
00:02:45